Divya Akshintala, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1215343603
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $325 of the $375 with a category attached, or 86.7%. 7 manufacturers reported payments, led by Insulet Corporation at 30.3% of the total. Reporting peaked in 2024 at $166 and has fallen 67.4% since, to $54 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OH, where the typical reported total is $1,051.
Across 16 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$114
- Dexcom, Inc.$101
- Abbott$74
- Medtronic$34
- Bayer$20
- BETA Bionics, Inc.$18
- plus $16 from 1 others
What the payments were for
- Food & beverage$32587%
- Education$5013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 3 | $114 |
| Dexcom, Inc. | 6 | $101 |
| Abbott | 2 | $74 |
| Medtronic | 2 | $34 |
| Bayer | 1 | $20 |
| BETA Bionics, Inc. | 1 | $18 |
| RGH Enterprises LLC | 1 | $16 |
How this compares
$375 in reported general payments places this provider in the 30th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 222 | $336,375 |
| TrulicityDulaglutide | 142 | $178,727 |
| JardianceEmpagliflozin | 139 | $153,957 |
| MounjaroTirzepatide | 106 | $117,662 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $66,195 |
| JanuviaSitagliptin Phosphate | 33 | $33,491 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $30,164 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $28,346 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 159 | $27,901 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 11 | $27,724 |
| ProliaDenosumab | 16 | $27,203 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $23,574 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $21,123 |
| FarxigaDapagliflozin Propanediol | 11 | $18,224 |
| Humalog Kwikpen U-100Insulin Lispro | 45 | $17,183 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.